St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Related Stories
Some tumors kill neighboring healthy cells to fuel growth / 5 wks
MYC overactivity enables DNA repair and chemotherapy resistance in tumours / 2 months
CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 13 days
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 7 wks
Mass spectrometry platform could cut drug discovery to hours / 27 days
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 4 months
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pharmaceuticals, Biotech, Corporate Takeover, Hearing Loss and look for the RSS link.
StackHealth Time Machine